Tag Archives: Clinical trial

let’s not forget: Smallpox (1908). Eradicated thanks to marvels of vaccinations — Lindsey Fitzharris (@DrLindseyFitz)


New Multiple Myeloma Drug Set to Begin Clinical Trials|Specialty Pharmacy TIme


Specialty Pharmacy News

Treatment inhibits key process that enables cancer cells to multiply.

Researchers in London plan to begin clinical trials on a significant new treatment for multiple myeloma by the end of next year.

In laboratory testing, the drug, known as DTP3, killed myeloma cells within human cells and mice without causing any toxic side effects. In a paper published on October 13, 2014 in Cancer Cells, researchers outlined how the drug inhibits a key process that allows cancer cells to multiply.

“Lab studies suggest that DTP3 could have therapeutic benefit for patients with multiple myeloma and potentially several other types of cancer, but we will need to confirm this in our clinical trials, the first of which will start next year,” said lead researcher Professor Guido Franzoso in a press release.

DTP3 was developed through an evaluation of the mechanisms that enable cancer cells to continue multiplying beyond their normal lifespan. Specifically, the researchers studied a protein called nuclear factor kappa B (NF-kB), which plays a key role in inflammation, in addition to immune and stress response systems.

“We had known for many years that NF-kB is very important for cancer cells, but because it is also needed by healthy cells, we did not know how to block it specifically,” Franzoso said. “The discovery that blocking the GADD45β/MKK7 segment of the NF-κB pathway with our DTP3 peptide therapeutic selectively kills myeloma cells could offer a completely new approach to treating patients with certain cancers, such as multiple myeloma.” – See more at: http://www.specialtypharmacytimes.com/news/New-Multiple-Myeloma-Drug-Set-to-Begin-Clinical-Trials#sthash.XGAUTmks.Gyz2Cy02.dpuf

via New Multiple Myeloma Drug Set to Begin Clinical Trials.

this pressed-from Science Friday: Giving Viruses a License to Kill…Cancer


Giving Viruses a License to Kill…Cancer.

Giving Viruses a License to Kill…Cancer The lab of Dr. Mark Federspiel at the Mayo Clinic, where the measles virus is being grown in bioreactors for the next clinical trial coming up in September. Photo by Mayo Clinic

news: Measles Virus Used to Wipe Out Cancer (multiple myeloma)


Measles Virus Used to Wipe Out Cancer

Researchers are cautiously optimistic about an experimental cancer treatment that uses a modified measles virus to target and kill cancerous cells. Two out of six multiple myeloma patients who were treated with extremely high doses of the engineered viruses responded to the treatment, with one appearing to enter into complete remission. These two patients were found to have few or no circulating measles antibodies, important because this affords the virus a chance to attack the cancer cells before the patient’s immune system begins fighting off the virus. More… Discuss

Enhanced by Zemanta

Blood from Young Improves Memory in Old


Blood from Young Improves Memory in Old

Transfusing the blood plasma of young mice into older mice allowed them to perform better on tests of memory than their peers, suggesting that some factor or factors in the blood of the young can reverse certain aging processes. Researchers are now trying to identify which factors accomplish this and whether similar benefits would be seen in human trials. More… Discuss

Enhanced by Zemanta
Video

Spring is back…and so I’m on the trail (my photo collection)


This slideshow requires JavaScript.

Enhanced by Zemanta

VITAMIN C POSSIBLE CANCER FIGHTER


Vitamin C Possible Cancer Fighter

In the 1970s, Nobel Prize – winning chemist Linus Pauling reported success treating cancer with intravenous vitamin C. However, when clinical trials of oral vitamin C failed to yield results, the medical establishment largely abandoned this line of research. Now, decades later, researchers are finding that injected vitamin C can kill cancer cells without harming healthy cells and that, when used in combination with chemotherapy, it can slow tumor growth and curb chemotherapy side effects. More… Discuss

 

Enhanced by Zemanta

NEWS: PEANUT ALLERGY TRIAL SUCCESS


Peanut Allergy Trial Success

When it comes to food allergiespeanut allergies are the most deadly, but perhaps not for long. A clinical trial involving 85 children with peanut allergies successfully increased the tolerance of 84% to five peanuts a day after six months. At the start of the trial, participants were given a daily dose of peanut protein powder equivalent to one 70th of a peanut, too little to initiate an allergic reaction. Over the course of the study, the dose was slowly increased under careful medical observation, desensitizing most of the children to small amounts of peanuts. More… Discuss

 

Enhanced by Zemanta

Corul National de Camera MADRIGAL Concert traditional de colinde “Rasaritul Cel de Sus” 2013